About

A commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals that address patients’ unmet medical needs, with an initial focus on addressing anaemia associated with renal and gastrointestinal disorders.

At a glance

Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs.

Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030’s.

Non-Executive Chairman

Dr Andrew Heath

By any measure the past twelve months have been very busy, hugely exciting and a period of remarkable achievement for Shield Therapeutics. Less than six years after starting operations Shield achieved a marketing authorisation for Feraccru®, the first oral prescription pharmaceutical product approved across Europe for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.

CEO & Founder

Carl Sterritt

Shield has been transforming itself from a wholly development-focused and private company into a listed and increasingly commercially-focused, customer-facing organisation. We are now well positioned to become a fast growing, independent, international specialty pharmaceutical company and, due to the strength of our products and team, and with great thanks to all of our supportive shareholders, I look forward to the future with great excitement.

What sets us apart

  • Near term revenue potential

    The Group received MA approval in Europe for Feraccru® in February 2016 and undertook our first commercial launch of Feraccru® in the UK with our own commercial team in May 2016. Roll-out across Europe directly or via commercial partners will continue through 2016 and 2017.

  • Lead product Feraccru®

    Currently approved in Europe offers a number of important advantages compared to current standards of care for IDA.

  • Large market opportunities with unmet needs

    Feraccru® addresses a large and structurally growing market with significant potential in the near term. GfK estimates there are approximately 1.4 to 1.5 million patients in Europe and the US with IBD who have the potential to be treated for IDA of which a significant proportion are currently ineffectively treated. GfK also estimates that there are over 3.4 million patients in the EU and US with IDA and CKD.

  • Experienced management team with extensive expertise

    The skilled senior management team and board of directors provide strong leadership for the Company’s future growth.

  • Opportunity to create operational leverage across the product portfolio

    Feraccru® is commercialised using a mix of our own commercial operations in major markets and best in class local commercial partners in other non-core markets. Our assets are naturally targeted to specialist prescribers based in hospitals and private clinics.

  • Strong intellectual property protection

    The Group’s assets are supported by a suite of strong intellectual property rights including key patents in major markets. The Group’s marketed product, Feraccru®, for the treatment of IDA in adult patients with IBD has exclusive IP rights until the mid-2030’s.

  • Attractive financial profile

    The proceeds of the February 2016 IPO, together with the result of the fundraise through the exercise of the Warrants (see financial review, page 15) provides a strong financial platform for the growth of the Group. The Directors expect the Company to generate near term revenues with inherently high gross margins following the recent launch of Feraccru®. Whilst development activity will continue for the foreseeable future, the Directors believe that the level of R&D spend should be relatively modest bearing in mind the potential revenues from Feraccru® and PT20.

London, UK

120 New Cavendish Street
London
W1W 6XX

t+44 (0) 207 186 8500

einfo@shieldtx.com

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

einfo@shieldtx.com

Wollerau, Switzerland

Sihleggstrasse 23,
8832 Wollerau
Switzerland

t+41 (0) 435 080 781

einfo@shieldtx.com

Munich, Germany

München 5 Höfe
Theatinerstrasse 11
DE- 80333 München

t+49 (0) 89 710 42 2246

einfo.de@shieldtx.com